Angiogenic targets

Angiogenic targets refer to a collective group of proteins and signaling pathways that regulate the formation of new blood vessels from existing ones, a process essential for both physiological development and pathological progression. The most prominent members include the Vascular Endothelial Growth Factor (VEGF) family and its receptors (VEGFR-1, -2, and -3), which drive endothelial cell survival and migration [1][3]. Other critical components include Platelet-Derived Growth Factor (PDGF), Fibroblast Growth Factor (FGF), and Angiopoietins, which facilitate vessel stabilization and maturation [2][5]. In diseases such as solid tumors and neovascular ocular disorders, these targets are often overexpressed, leading to disorganized and leaky vessel growth that supports tumor expansion or causes vision loss [4]. Therapeutic strategies targeting these molecules include monoclonal antibodies that neutralize circulating ligands and small-molecule inhibitors that block receptor tyrosine kinase activity [2][4]. While these therapies have revolutionized the treatment of various cancers and blinding eye diseases, they are associated with systemic side effects like hypertension and impaired wound healing due to the inhibition of normal vascular maintenance [1][5].

Other names

Pro-angiogenic factorsAngiogenesis-related targetsVascular growth factors

Inhibition of pro-angiogenic signaling through ligand sequestration, competitive receptor binding, or inhibition of intracellular tyrosine kinase domains [2][4].